Wong ECL, Kapoor A. Epidemiology of prostate and kidney cancer in the Aboriginal population of Canada: A systematic review. Can Urol Assoc J. 2017;11(5):E222–32.

Article  PubMed  PubMed Central  Google Scholar 

Trama A, Botta L, Nicolai N, Rossi PG, Contiero P, Fusco M, et al. Prostate cancer changes in clinical presentation and treatments in two decades: an Italian population-based study. Eur J Cancer. 2016;67:91–8.

Article  PubMed  Google Scholar 

Kamibeppu T, Yamasaki K, Nakahara K, Nagai T, Terada N, Tsukino H, et al. Caveolin-1 and -2 regulate cell motility in castration-resistant prostate cancer. Res Rep Urol. 2018;10:135–44.

CAS  PubMed  PubMed Central  Google Scholar 

Swami U, McFarland TR, Nussenzveig R, Agarwal N. Advanced prostate cancer: treatment advances and future directions. Trends in Cancer. 2020;6(8):702–15.

Article  CAS  PubMed  Google Scholar 

Achard V, Putora PM, Omlin A, Zilli T, Fischer S. Metastatic prostate cancer: treatment options. Oncology. 2022;100(1):48–59.

Article  CAS  PubMed  Google Scholar 

Yamada Y, Beltran H. The treatment landscape of metastatic prostate cancer. Cancer Lett. 2021;519:20–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Terada N, Akamatsu S, Kobayashi T, Inoue T, Ogawa O, Antonarakis ES. Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications. Ther Adv Med Oncol. 2017;9(8):565–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Engelman JA, Zhang XL, Lisanti MP. Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett. 1998;436(3):403–10.

Article  CAS  PubMed  Google Scholar 

Jenkins R, Takahashi S, DeLacey K, Bergstralh E, Lieber M. Prognostic significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in stage T3N0M0 prostate cancer. Genes Chromosomes Cancer. 1998;21(2):131–43.

Article  CAS  PubMed  Google Scholar 

Nassar ZD, Hill MM, Parton RG, Francois M, Parat MO. Non-caveolar caveolin-1 expression in prostate cancer cells promotes lymphangiogenesis. Oncoscience. 2015;2(7):635–45.

Article  PubMed  PubMed Central  Google Scholar 

Ayala G, Morello M, Frolov A, You S, Li R, Rosati F, et al. Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression. J Pathol. 2013;231(1):77–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thompson TC, Tahir SA, Li L, Watanabe M, Naruishi K, Yang G, et al. The role of caveolin-1 in prostate cancer: clinical implications. Prostate Cancer Prostatic Dis. 2009;13(1):6–11.

Article  PubMed  PubMed Central  Google Scholar 

Guo Z, Hu X, Xing Z, Xing R, Lv R, Cheng X, et al. Baicalein inhibits prostate cancer cell growth and metastasis via the caveolin-1/AKT/mTOR pathway. Mol Cell Biochem. 2015;406(1–2):111–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao Y, Li L, Li T, Ma L, Yuan M, Sun W, et al. Simvastatin delays castration-resistant prostate cancer metastasis and androgen receptor antagonist resistance by regulating the expression of caveolin-1. Int J Oncol. 2019;54(6):2054–68.

CAS  PubMed  PubMed Central  Google Scholar 

Yuan S, Wang L, Chen X, Fan B, Yuan Q, Zhang H, et al. Triptolide inhibits the migration and invasion of human prostate cancer cells via Caveolin-1/CD147/MMPs pathway. Biomed Pharmacother. 2016;84:1776–82.

Article  CAS  PubMed  Google Scholar 

Goh M, Chen F, Paulsen MT, Yeager AM, Dyer ES, Ljungman M. Phenylbutyrate attenuates the expression of Bcl-X (L), DNA-PK, caveolin-1, and VEGF in prostate cancer cells. Neoplasia. 2001;3(4):331–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Iguchi K, Matsunaga S, Nakano T, Usui S, Hirano K. Inhibition of caveolin-1 expression by incadronate in PC-3 prostate cells. Anticancer Res. 2006;26(4B):2977–81.

CAS  PubMed  Google Scholar 

Ifere GO, Equan A, Gordon K, Nagappan P, Igietseme JU, Ananaba GA. Cholesterol and phytosterols differentially regulate the expression of caveolin 1 and a downstream prostate cell growth-suppressor gene. Cancer Epidemiol. 2010;34(4):461–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang X, Liu Z, Yang Z. Expression and clinical significance of Caveolin-1 in prostate cancer after transurethral surgery. BMC Urol. 2018;18(1):102.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Williams TM, Lisanti MP. The caveolin proteins. Genome Biol. 2004;5(3):214.

Article  PubMed  PubMed Central  Google Scholar 

Scherer PE, Okamoto T, Chun M, Nishimoto I, Lodish HF, Lisanti MP. Identification, sequence, and expression of caveolin-2 defines a caveolin gene family. Proc Natl Acad Sci USA. 1996;93(1):131–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fridolfsson HN, Roth DM, Insel PA, Patel HH. Regulation of intracellular signaling and function by caveolin. FASEB J. 2014;28(9):3823–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sonnino S, Prinetti A. Sphingolipids and membrane environments for caveolin. FEBS Lett. 2009;583(4):597–606.

Article  CAS  PubMed  Google Scholar 

Wu HC, Chang CH, Tsou YA, Tsai CW, Lin CC, Bau DT. Significant association of caveolin-1 (CAV1) genotypes with prostate cancer susceptibility in Taiwan. Anticancer Res. 2011;31(2):745–9.

CAS  PubMed  Google Scholar 

Bennett N, Hooper JD, Lee CS, Gobe GC. Androgen receptor and caveolin-1 in prostate cancer. IUBMB Life. 2009;61(10):961–70.

Article  CAS  PubMed  Google Scholar 

Song KS, Tang Z, Li S, Lisanti MP. Mutational analysis of the properties of caveolin-1. A novel role for the C-terminal domain in mediating homo-typic caveolin-caveolin interactions. J Biol Chem. 1997;272(7):4398–403.

Article  CAS  PubMed  Google Scholar 

Sargiacomo M, Scherer PE, Tang Z, Kubler E, Song KS, Sanders MC, et al. Oligomeric structure of caveolin: implications for caveolae membrane organization. Proc Natl Acad Sci USA. 1995;92(20):9407–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schlegel A, Schwab RB, Scherer PE, Lisanti MP. A role for the caveolin scaffolding domain in mediating the membrane attachment of caveolin-1. The caveolin scaffolding domain is both necessary and sufficient for membrane binding in vitro. J Biol Chem. 1999;274(32):22660–7.

Article  CAS  PubMed  Google Scholar 

Woodman SE, Schlegel A, Cohen AW, Lisanti MP. Mutational analysis identifies a short atypical membrane attachment sequence (KYWFYR) within caveolin-1. Biochemistry. 2002;41(11):3790–5.

Article  CAS  PubMed  Google Scholar 

Wong TH, Dickson FH, Timmins LR, Nabi IR. Tyrosine phosphorylation of tumor cell caveolin-1: impact on cancer progression. Cancer Metastasis Rev. 2020;39(2):455–69.

Article  CAS  PubMed  Google Scholar 

Bernatchez P. Endothelial caveolin and its scaffolding domain in cancer. Cancer Metastasis Rev. 2020;39(2):471–83.

Article  CAS  PubMed  Google Scholar 

Sotgia F, Martinez-Outschoorn UE, Howell A, Pestell RG, Pavlides S, Lisanti MP. Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu Rev Pathol. 2012;7:423–67.

Article  CAS  PubMed  Google Scholar 

Ketteler J, Klein D. Caveolin-1, cancer and therapy resistance. Int J Cancer. 2018;143(9):2092–104.

Article  CAS  PubMed  Google Scholar 

Okamoto T, Schlegel A, Scherer PE, Lisanti MP. Caveolins, a family of scaffolding proteins for organizing “preassembled signaling complexes” at the plasma membrane. J Biol Chem. 1998;273(10):5419–22.

Article  CAS  PubMed  Google Scholar 

Kogo H, Aiba T, Fujimoto T. Cell type-specific occurrence of caveolin-1alpha and -1beta in the lung caused by expression of distinct mRNAs. J Biol Chem. 2004;279(24):25574–81.

Article  CAS  PubMed  Google Scholar